Foreign firms including Merck KGaA, Boehringer Ingelheim, Takeda and Sanofi’s vaccines business are being led by women in India, a fiercely competitive, largely out-of-pocket market. There’s a lot riding on these female leaders as they seek to drive business growth and potentially change the paradigm around the gender gap in pharma at the top.
Wider-ranging new draft rules suggest that physicians in India should not engage in educational activity sponsored by pharma and urges them to declare financial earnings and benefits received from industry via an affidavit. The Pink Sheet discusses with industry experts some of the nuances and seeming loopholes in the rules, currently in self-regulatory mode but with penalties proposed for violation.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.